KIT Inhibition by Imatinib Helps Severe Refractory Asthma

Share this content:
KIT Inhibition by Imatinib Helps Severe Refractory Asthma
KIT Inhibition by Imatinib Helps Severe Refractory Asthma

MONDAY, May 22, 2017 (HealthDay News) -- Imatinib (Gleevec) may effectively treat severe refractory asthma, according to research published in the May 18 issue of the New England Journal of Medicine.

Elliot Israel, M.D., director of the respiratory therapy department at Brigham and Women's Hospital in Boston, and colleagues recruited 62 patients with poorly controlled severe asthma with airway hyperresponsiveness despite maximal medical therapy. All were randomly assigned to take either imatinib or a placebo pill once daily during the six-month trial.

The researchers found that imatinib was associated with a reduction in mast-cell activity. Allergy challenge tests demonstrated a decrease in airway reactivity among patients taking imatinib. Side effects in the intervention group included muscle cramps and hypophosphatemia.

"In patients with severe asthma, imatinib decreased airway hyperresponsiveness, mast-cell counts, and tryptase release," the authors write. "These results suggest that KIT-dependent processes and mast cells contribute to the pathobiologic basis of severe asthma."

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures imatinib and provided the drug for the study free of charge.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

U.S. High School Students Report Sport-Linked Concussion

U.S. High School Students Report Sport-Linked Concussion

Overall, 15.1 percent of students reported having at least one concussion in the previous 12 months

Corneal Abnormalities Seen With Down Syndrome

Corneal Abnormalities Seen With Down Syndrome

More than 70 percent of patients in Down syndrome group had traits compatible with keratoconus

Many Childhood CA Survivors Not Concerned About Future Health

Many Childhood CA Survivors Not Concerned About Future ...

Even among those exposed to high radiation doses, one-third not concerned about developing cancer

is free, fast, and customized just for you!




Already a member?

Sign In Now »